Abstract: Objective  To investigate the effect of resveratrol on pulmonary function and cardiac function in SD rats with chronic obstructive pulmonary disease and pulmonary heart disease.
Methods  Forty-five adult male SD rats were randomly divided into resveratrol group, glucocorticoid group and control group with 15 rats in each group. The resveratrol group was given resveratrol intragastric administration for 28 days, the glucocorticoid group was given Budesonide aerosol inhalation for 28 days, and the control group was given normal saline for 28 days. The lung function(CL), peak expiratory flow(PEF), maximum mid expiratory flow curve(MMF) and forced expiratory volume in first 0.3 second/forced vital capacity were compared between the three groups before and after treatment, FEV0.3/FVC, left ventricular ejection fraction(LVEF), left ventricular end diastolic diameter(LVEDd), interventricular septal thickness(IVST) and left ventricular posterior wall thickness(LVPWT), Right ventricular free wall mass, left ventricle and interventricular septum mass, right ventricular free wall mass/left ventricular+ventricular septum mass ratio(RV/（LV+S） were observed.
Results  After the intervention, the levels of CL, PEF and MMF in the three groups were lower than those before the intervention, and the levels of FEV0.3/FVC in the resveratrol group were higher than those in the glucocorticoid group and the control group, and the levels of CL, PEF, MMF and FEV0.3/FVC in the glucocorticoid group were higher than those in the control group(P＜0.05). LVEF, LVEDd, IVST, LVPWT, right ventricular free wall mass, left ventricular+interventricular septal mass and RV/（LV+S） of the three groups were higher than those before intervention. LVEF of resveratrol group was higher than that of glucocorticoid group and control group. LVEDd, IVST, LVPWT, right ventricular free wall mass, left ventricular+ventricular septum mass, RV/（LV+S） were lower than those of glucocorticoid group and control group, and LVEF of glucocorticoid group was higher than that of control group LVEDd, IVST, LVPWT, right ventricular free wall mass, left ventricle+interventricular septum mass, RV/（LV+S） in the control group were lower than those in the control group(P＜0.05). The total incidence of adverse reactions in glucocorticoid group was higher than that in resveratrol group and control group(P＜0.05).
Conclusion  Compared with glucocorticoids, resveratrol can effectively improve the lung function of SD rats with chronic obstructive pulmonary disease complicated with pulmonary heart disease, delay the deterioration of cardiac function and structure, improve the prognosis, and avoid the occurrence of severe adverse reactions such as hyperglycemia and osteoporosis caused by glucocorticoids, which has both effectiveness and safety. The above mechanism of resveratrol needs to be further studied. The study confirmed that it is expected to provide more effective clinical basis for the treatment of chronic obstructive pulmonary disease complicated with pulmonary heart disease.

Key words: pulmonary disease, chronic obstructive, pulmonary heart disease, resveratrol